In its fourth quarter 2024 investor letter, Brown Advisors Global Leaders Strategy emphasized stocks such as Illumina, Inc. (NASDAQ:ILMN). Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array ...

Conclusion of DME Impact on Clinical Outcome of AI Therapy So far, evidence supporting an impact of genetic variation of DMEs on AI therapy outcome in breast cancer patients is limited. Further ...

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...

Follow us on Facebook and join our Telegram channel for the latest updates. Prime Minister and Finance Minister Lawrence Wong mentioned Illumina, the Nasdaq-listed biotechnology firm headquartered in ...

For the first time, China has put American genome-sequencing equipment manufacturer Illumina on its “unreliable entity list”. The move was a direct counter to the US imposing sanctions on Beijing ...

That morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price target ...

Although the role of DMEs for AI outcome is less investigated compared with tamoxifen, initial studies addressed pharmacogenetic relationships that may indicate potential clinical implications ...

(RTTNews) - Below are the earnings highlights for Illumina Inc. (ILMN): Earnings: $187 million in Q4 vs. -$176 million in the same period last year. EPS: $1.17 in Q4 vs. -$1.11 in the same period ...

China's "blacklist of entities" now has two more entries -- Illumina and fashion conglomerate PVH-- after its government put the companies on notice late Monday. The move is clearly a retaliatory ...

China placed Illumina on its unreliable entities list. Being placed on the unreliable entities list, opens the company up to sanctions from the Chinese government. Our government trade tracker ...

Illumina reported Q3 2024 revenue of $1.08 billion -- in line with analysts' consensus estimate. Non-GAAP EPS was $1.14, exceeding the $0.879 consensus and indicating strong cost control. Despite ...